Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Mallinckrodt
Baxter
Cipla
Express Scripts
AstraZeneca

Generated: July 19, 2019

DrugPatentWatch Database Preview

Patent: 8,591,943

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,591,943
Title:Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
Abstract: The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.
Inventor(s): Deng; Yongqi (Newton, MA), Sun; Binyuan (Chestnut Hill, MA), Zeng; Hongbo (Westford, MA), Richards; Matthew (Somerville, MA), Shipps, Jr.; Gerald W. (Stoneham, MA), Cheng; Cliff C. (Cambridge, MA), Zhao; Yinyan (Rockville, MD), McRiner; Andrew (Melrose, MA), Meng; Zhaoyang (Lansdale, PA), Nan; Yang (Lansdale, PA), Patel; Mehul F. (Willow Grove, PA), Wrona; Iwona E. (Sharon, MA), Reddy; Panduranga Adulla (Walpole, MA), Eklov; Brian M. (Kalamazoo, MI), Tang; Shuyi (Belmont, MA), Liu; Duan (Arlington, MA), Mandal; Amit K. (Shrewsbury, MA), Zhao; Lianyun (Blue Bell, PA), Siddiqui; M. Arshad (Newton, MA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:13/263,193
Patent Claims:see list of patent claims

Details for Patent 8,591,943

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up Merck Sharp & Dohme Corp. (Rahway, NJ) ➤ Sign Up RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up Merck Sharp & Dohme Corp. (Rahway, NJ) ➤ Sign Up RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ➤ Sign Up Merck Sharp & Dohme Corp. (Rahway, NJ) ➤ Sign Up RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19 ➤ Sign Up Merck Sharp & Dohme Corp. (Rahway, NJ) ➤ Sign Up RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up Merck Sharp & Dohme Corp. (Rahway, NJ) ➤ Sign Up RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Chubb
Julphar
Express Scripts
Merck
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.